Analysts Set Inventiva S.A. (NASDAQ:IVA) Target Price at $17.00

Shares of Inventiva S.A. (NASDAQ:IVA) have been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $17.00.

A number of analysts recently commented on the stock. Stifel Nicolaus lowered their price objective on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Canaccord Genuity Group boosted their target price on Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, April 8th. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Inventiva in a research note on Monday, April 1st. Finally, Lifesci Capital reissued an “outperform” rating on shares of Inventiva in a research note on Friday, January 5th.

Inventiva Stock Down 2.5 %

IVA opened at $3.16 on Friday. The company has a fifty day moving average price of $3.63 and a two-hundred day moving average price of $3.90. Inventiva has a 52 week low of $2.22 and a 52 week high of $5.05.

Hedge Funds Weigh In On Inventiva

A hedge fund recently raised its stake in Inventiva stock. Commonwealth Equity Services LLC increased its stake in shares of Inventiva S.A. (NASDAQ:IVA) by 20.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,435 shares of the company’s stock after buying an additional 4,155 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Inventiva were worth $103,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.